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abstract
After the foundation of the EORTC in 1962, the Radio-Chemotherapy Group within
this organization split in 1973 into two groups. One of these groups, concentrating
on Hodgkin’s and Non-Hodgkin’s Lymphoma, later became the Lymphoma Group
while the other became the Radiotherapy Group. During the 1990’s the latter changed
its name to the Radiation Oncology Group (ROG), underscoring its position within
the ﬁeld of multidisciplinary oncology research. By 2011 the ROG had initiated
or participated in 83 clinical studies, of which more than 73% were randomized
phase III trials. It has concentrated on almost every disease site from brain to
gynecological tumors with emphasis on brain, head and neck, breast, prostate, and
lower gastro-intestinal tumours. The ROG has published several hundreds peer-
reviewed articles, including publications in prestigious journals such as the New
England Journal of Medicine or Lancet Oncology. Since its foundation, the ROG has
understood the importance of conducting a proper Radiotherapy Quality Assurance
(RT-QA) program for every clinical trial aiming at guaranteeing the quality of
radiotherapy, i.e. minimizing any uncertainties in the conduction of trials. As
radiotherapy evolved from two-dimensional to Intensity Modulated Radio Therapy,
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this program has progressively matured with time to be part of a worldwide RT-QA
consortium in 2012.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
Following the foundation of the EORTC in 1962, the
Radio-Chemotherapy Group within this organization
split into two groups in 1973. One of these groups,
concentrating on Hodgkin’s and Non-Hodgkin’s Lym-
phoma, later became the EORTC Lymphoma Group,
while the other became the EORTC Radiotherapy Group.
During the 1990’s the latter changed its name to the
EORTC Radiation Oncology Group (ROG), underscoring its
position within the ﬁeld of multidisciplinary oncology
research.
In 1975 the Radiotherapy Group was led by pioneers,
such as Claude Lalanne, Jean-Claude Gofﬁn,Alain Laugier
and Jean-Claude Horiot. The ﬁrst protocol of this group
was activated in 1978, i.e., V-22781, pelvic radiotherapy
versus extended ﬁelds to para-aortic nodes in cervical
cancer. This study concluded that para-aortic irradiation
for all high-risk patients with cervical carcinoma was of
limited value, but that patients with a high probability of
local control can beneﬁt from extended ﬁeld irradiation
despite an increase in severe digestive complications. 1
Many other studies followed soon thereafter, and under
the guidance of Emmanuel van der Schueren, Jean-
Claude Horiot, and Walter van den Bogaert, the ROG
became the European leader in altered fractionation
schemes (mostly in head and neck cancers) and in
protocols addressing the use of radio-sensitizers. The
ﬁrst publication of a pilot study on the use of multiple
fractions per day in combination with the sensitizer
misonidazole in stage II and IV gliomas appeared in
1982 2 followed in 1985 by the publication of the results of
a further similar pilot study in advanced head and neck
cancer. 3
Very successful studies were organized in the ﬁeld
of breast and prostate cancer, not neglecting practice-
changing trials in a wide variety of ﬁelds, organized in
close collaboration with disease-oriented EORTC groups
especially in the ﬁelds of head and neck tumors,
lung cancer, anal cancer, rectal cancer, and brain
tumors. In the 1980’s and early 1990’s, the ROG was a
pioneer for testing the use of concomitant chemotherapy
(used as a radiosensitizer) and radiotherapy to improve
loco-regional tumor control in various tumor sites.
This combined approach was based on strong pre-
clinical and early clinical studies conducted in several
EORTC institutions. In non-small-cell lung carcinoma
(NSCLC) and anal carcinoma, phase III studies showed
that concomitant low-dose cisplatin and radiotherapy
or 5-FU–mitomycin and radiotherapy improved overall
survival (OS) and loco-regional control probability,
respectively. 4,5 These studies had an important impact
not only on patient management, but also on future
strategies that were subsequently tested within the
EORTC and other cooperative groups.
By 2011 the ROG had initiated or participated in
83 clinical studies, of which more than 73% were
randomized phase III trials. A selection of major
achievements of the ROG in brain, head and neck,
breast, prostate, and lower gastro-intestinal tumors are
presented in the following sections of this article. We’ll
conclude with a description of the Quality Assurance
program in radiotherapy (QA-RT), which was initiated
with the founding of the ROG.
2. Major clinical achievements
2.1. Brain tumors
Over the past 15 years the ROG has played a major role in
the progress of the treatment of important brain tumors,
including practice-changing studies in low-grade (LGG)
and high-grade glioma (HGG). This success has been
largely due to the excellent cooperation between the ROG
and the EORTC Brain Tumor Group (BTG).
In the EORTC 22845 trial on LGG, patients were
randomized between post-operative radiotherapy (RT)
and simple observation, and the results demonstrated
a highly signiﬁcant improvement in disease-free sur-
vival (DFS) in the RT arm but no difference in OS. 6 This
study was unique worldwide, and it still serves as a
major reference in the management of LGG. In another
ROG trial on LGG (EORTC 22844) two RT dose levels were
compared, and it was shown that the “low”-dose arm
(45Gy) was as good as the “high”-dose arm (59.4Gy) in
terms of tumor control and OS but with less toxicity. 7 The
latter study has contributed to determining the standard
RT dose in this type of tumor. The EORTC 22033–26033
trial is an important intergroup study comparing post-
operative RT to post-operative temozolomide (TMZ) in
LGG. At the time of writing, the results are not yet
known.
In HGG, especially in glioblastoma multiforme (GBM),
the ROG has pioneered innovative RT approaches such
as accelerated RT (ART) 8 and the combination of
ART with carbogen and nicotinamide in the “ARCON”
trial. 9 However, the turning point in GBM came with
the temozolomide trial (EORTC 22981–26981) which
compared RT with and without TMZ. 10 The study was
elaborated following a very successful brainstorming
Open access under CC BY-NC-ND license.
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meeting organized by the ROG in Geneva in September
1997, and shortly thereafter a promising phase II
study was initiated. 11 After some initial difﬁculties, this
randomized trial became a joint study of the ROG and
the BTG and achieved a very quick accrual. This trial, the
EORTC 22981–26981 trial, is considered a breakthrough
trial, since it showed for the ﬁrst time in 30 years a
highly signiﬁcant improvement in OS in GBM with the
use of concomitant and adjuvant TMZ chemotherapy
with RT. The trial also demonstrated that TMZ with
RT was of most beneﬁt to patients whose tumors
presented with a methylation of the MGMT promoter
gene. 12 It also showed that with the combined TMZ−RT
treatment, patients in the best prognostic category
(RPA III) could beneﬁt from an amazing 3 and 5 year
survival of about 30%, a 4−5-fold increase compared to
RT alone. 13,14 In spite of the fact that most patients
eventually died from their GBM, the survival rates for the
more favorable patients (i.e., the methylated group and
the RPA III) were unthinkable before the publication of
EORTC 22981–26981. Currently, the TMZ−RT association
is the new standard in the management of this disease.
It also serves either as the backbone for any new
innovative approach 15 or as the standard arm to be
compared with in current and future trials in HGG,
not only in GBM, but also in other malignant glioma
such as anaplastic astrocytoma. In this regard, the ROG
is actively contributing to these novel approaches in
close cooperation with the BTG and also within the
framework of large intergroup studies. Finally, EORTC
22981–26981 has generated a dozen or more papers on
“side studies” in RT-QA, QOL, prognostic and predictive
factors, pathology studies, translational studies, health
economics etc. which have greatly contributed to a better
overall understanding of GBM.
2.2. Head-and-Neck tumors
Over the last three decades great strides have been made
in the management of locally advanced head and neck
squamous cell carcinoma. Undoubtedly, the EORTC has
been and is still playing a key role in this domain when
one considers the outcomes of the numerous prospective
trials it has activated for both post-operative treatments
as well as upfront conservative approaches.
One of the major issues addressed by the EORTC
before the turn of the century related to the impact of
altered fractionation schedules on outcome. As a world
premiere, the proof of concept was demonstrated by
the EORTC 22791 protocol. In advanced oropharyngeal
carcinomas, a 20% gain in local control was achieved
by using two fractions per day versus a single daily
fraction (p< 0.01). 16 An updated analysis conﬁrmed
that loco-regional improvement later converted into an
improved survival (p< 0.05). Although the hyperfrac-
tionation regimen reached a total dose of 80.5Gy, the
incidence and severity of late normal tissues radiation
effects were identical to those of the classical 70Gy
monofractionated schedule. Accelerated fractionation
was also addressed extensively by several protocols to
ﬁght tumor repopulation during treatment by reducing
the overall time with hyperfractionation. Again, our
group was ﬁrst to demonstrate the superiority (p< 0.02) of
the accelerated over the standard regimen in advanced
head and neck cancers (EORTC 22851, delivering 72Gy
in 5 weeks (3 fractions per day) versus 70Gy in 7 weeks
(a single daily fraction). 17 Both concepts and results
of hyperfractionation and accelerated radiotherapy were
reproduced a few years later by a number of other large
randomized protocols and meta-analyses.
Another axis of research at the EORTC has been
the postoperative management of stage III or IV
disease. Activated in 1994, EORTC trial 22931 tested
whether, compared to post-operative radiotherapy, ad-
juvant chemo-radiation improved prognosis. 18 In this
trial, a conventional schedule of radiotherapy (66Gy in
6.5 weeks) was compared to the same schedule, to which
was added 100mg of cisplatin per square meter of body
surface area on days 1, 22, and 43 of the course of
radiotherapy. One of the ﬁrst observations made in this
trial was that compliance with chemotherapy decreased
with the number of courses delivered, with only half of
the patients receiving the full protocol. Notwithstanding,
there was a signiﬁcant (p=0.04) difference in PFS − which
was the primary endpoint of the study − in favor of the
combined-therapy group over the radiotherapy group.
Also signiﬁcantly different were the OS rates, with 40% of
the patients alive at 5 years in the radiotherapy group
and 53% in the combined-therapy group and a 5-year
cumulative incidence of local or regional relapses of
31% and 18%, respectively. Interestingly, the cumulative
incidence of late complications was not signiﬁcantly
different across the two groups of patients. Thus, in
terms of evidence-based medicine, adjuvant treatment
with high-dose cisplatin plus radiotherapy was shown,
at a level I of evidence, to be more efﬁcacious than
radiotherapy alone in patients with unfavourable clinical
or pathological factors or both.
The ROG was also associated with the successful sto-
ries of laryngeal preservation strategies. The most recent
randomized phase III trial comparing two modalities
of chemoradiation for locally advanced squamous cell
carcinoma of the larynx is an example of the close
collaboration between the EORTC Head and Neck Cancer
Group and the ROG. 19
Many lessons can be drawn from these achievements.
One of them is that, while we have been good at
implementing protocols yielding signiﬁcant advances
in terms of efﬁcacy results, we probably did a less
convincing job when trying to match treatment intensity
and individual risk levels. This led, for a number of
some so-called “innovative” approaches, to gains in
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Fig. 1 – Cumulative incidence of ipsilateral breast cancer recurrence according to age. HR, hazard ratio; O, occurrences;
N, number of patients at risk, effect of a boost (16Gy) or no boost. Reproduced from JCO with permission.
therapeutic indices which remained somewhat inferior
to our expectations. Importantly, this caveat is bound
to be re-dimensioned by the increasing integration of
translational research into our clinical decision-making
processes, a point well taken by the EORTC.
2.3. Breast-conserving therapy
EORTC trial 10801 which compared modiﬁed radical
mastectomy (MRM) with breast-conserving therapy (BCT)
for patients with tumors up to 5 cm diameter, demon-
strated equivalent OS rates. 20 Two major issues had a
large impact on the subsequent trials: (1) signiﬁcant
differences in local control were seen between the
participating centers; (2) a high boost dose of 25Gy
resulted in a signiﬁcant proportion of the patients with
severe ﬁbrosis and a poor cosmetic outcome.
The difference in outcome per institute and the ﬁbrosis
of the high boost dose led to the next EORTC trial:
“Boost versus No Boost”, 22881/10882. In this trial, which
accrued 5318 patients with completely resected early
breast cancer, special attention was therefore paid to
quality assurance, ﬁbrosis and cosmetic scoring. The
boost dose was lowered from 25 to 16Gy, which was
randomized against no boost at all. This trial was one
of the ﬁrst for which a comprehensive quality assurance
program was organized, consisting of dummy runs,
clinical site visits, in vivo dose measurements (using
mailed thermoluminescent dosimeters) and a review of
clinical, pathological and radiotherapy data of a sample
of trial patients entered by each participating institution.
This trial demonstrated that in patients with early breast
cancer who underwent breast-conserving surgery and
received 50Gy of radiation to the whole breast, an
additional dose of 16Gy of radiation to the tumor bed
reduced the risk of local recurrence, especially in patients
younger than 50 years of age. 21
In contrast to the older trial, and probably at
least in part as a consequence of all the efforts
to optimize the quality of treatment, no signiﬁcant
difference was found in local recurrence rates between
the participating institutes. Even the local recurrence
rate was signiﬁcantly lower in the “Boost No Boost
trial”. In this boost trial, young age appeared to be
the most independent signiﬁcant patient factor related
to local recurrence. 22 The absolute effect of the boost,
which reduced the local recurrence rate relatively by
41% overall, was therefore much more marked for
younger patients, as displayed in Fig. 1. Nomograms
have been developed to predict in individual patients the
impact of a boost dose of 16Gy on the ipsilateral breast
relapse (http://research.nki.nl/ibr) and ﬁbrosis. 23,24
It is important to see this reduction in the local
recurrence rate over time in these two EORTC trials. 22
The explanation of this continuous improvement lies in
a number of factors, including technical and diagnostic
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Fig. 2 – Overall survival for prostate cancer patients with a high metastatic risk treated with radiotherapy alone (70Gy in 7
weeks) or the same radiotherapy plus LH-RH agonist for 3 years.
ones and the increasing use of adjuvant systemic
treatment.
2.4. Prostate tumors
In the mid-1980’s the EORTC ROG decided to launch
phase III trials to improve the treatment efﬁcacy
of locally advanced prostate carcinoma (PCa) treated
by conventional external radiotherapy (RT) and of
localized PCa managed by radical prostatectomy (RP).
Within the frame of a multi-disciplinary approach we
proposed (1) to evaluate the combination of RT and
long-term androgen deprivation therapy (ADT) with a
luteinizing hormone releasing hormone (LHRH) agonist
to potentiate RT and decrease the metastatic risk,
and (2) to assess the role of immediate post-operative
irradiation in patients with 1 pathological risk factors
(i.e., capsule perforation, invasion of seminal vesicles
and/or positive margins) to improve local control and
biochemical/clinical progression-free survival (PFS).
EORTC trial 22863 accrued 415 patients (1987−95) and
compared pelvic RT plus 3-year ADT to RT alone and
ADT at relapse. This trial was the ﬁrst to show a
major improvement in OS resulting from this combined
approach which became a gold standard. 25,26 The 10-year
results showed a striking improvement of OS from
39.8% for the RT alone group to 58.1% for the combined
group (p=0.0004) (Fig. 2). 27 In this setting the duration of
ADT, however, remained controversial. Short-term ADT
(RT with 6 months ADT) was then compared to long-
term ADT (RT with 3 years ADT in EORTC trial 22961,
which enrolled 1113 men between 1997 and 2001). After
a median follow-up of 6.4 years, the combination of RT
and 6 months of ADT was declared inferior to RT plus
3 years of ADT (p=0.64 for non-inferiority), meanwhile
quality of life did not signiﬁcantly differ between the
two groups. 28 Thereafter, the concept of a combined
approach was moved to intermediate- and high-risk
localized PCa to address the impact of conformal and
advanced techniques of RT (3D-CRT or IMRT) with dose
escalation (70, 74, 78Gy) +/− 6 months of ADT. Trial
22991 registered 820 men (2001–2008) and its preliminary
results are pending.
In a different approach, patients with radical prostate-
ctomy (RP) were randomized between immediate post-
operative RT or deferred RT in case of relapse. EORTC
trial 22911 enrolled 1005 patients with pT3a−b or with
an R1 resection between 1992 and 2001. The 5-year
clinical and biochemical PFS was signiﬁcantly improved
in the RT group (72.2% versus 51.8%, p< 0.0001), as well
as the clinical PFS (p=0.004). The 5-year cumulative
loco-regional failure rate was signiﬁcantly lower in the
RT group (p< 0.0001), i.e., 5.2% versus 15.2% in the control
group. 29 The 10-year results showed that conventional
post-operative irradiation improved biochemical PFS and
local control without signiﬁcantly impacting on distant
metastases or OS. EORTC trial 22043 (open in 2009) is
now assessing the role of short-term ADT with an LHRH
agonist for high-risk postoperative patients submitted to
immediate 3D-CRT or IMRT after RP.
For all of these trials, quality assurance studies were
implemented aiming at optimizing RT delivery from
conventional irradiation to 3D-CRT or IMRT. 30
2.5. Anal canal and rectal tumors
Over the last decades, the ROG has pioneered major
clinical studies that established chemoradiation (CRT) as
a new paradigm in gastrointestinal cancers.
In 1987, in collaboration with the EORTC Gastro-
intestinal Tract Cancer Group (GI Group), the ROG
launched a phase III trial that investigated a potential
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gain of combining ﬂuorouracil (5FU)–mitomycin-C (MMC)
with radiotherapy in locally advanced anal cancer
(EORTC trial 22861). As compared to RT alone, the
combined treatment modality showed a signiﬁcant
improvement in loco-regional control and a gain in
colostomy-free survival. 5 A similar trial conducted in the
UK showed that the beneﬁt was also observed in early
disease. 31 These two pivotal trials have established CRT
as standard treatment in anal canal cancer.
The phase II EORTC trial 22953 was initiated in 1996 by
the ROG and GI Group to (1) test the feasibility of reducing
the gap between the two RT sequences (from 6 weeks to
2 weeks), (2) deliver 5FU−MMC during all the RT duration
rather than during the ﬁrst sequence only, and (3) reduce
the dose of elective node irradiation from 45Gy (in study
22861) to 36Gy. Tolerability was excellent. As compared
to EORTC trial 22861, the new protocol appeared to be
more efﬁcient on local control, colostomy-free interval
and OS. 32 Despite the lack of a randomized comparative
study this new protocol was accepted as the standard for
further studies.
The ROG then initiated a randomized phase II trial
to assess the feasibility and activity of CRT with MMC
and cisplatin in comparison to CRT with 5FU−MMC.
The new combination shown higher response rates and
was recommended to be tested in phase III trials. 33 A
pooled analysis of radiotherapy parameters in all phase
II and III studies conducted worldwide is ongoing under
the auspices of the ROG (PARADAC study).
For the last 15 years there have been no new
advances in the treatment of anal cancer. The intriguing
and pending question is its exceptional radiosensitivity
that should be explored through translational studies
questioning in particular a potential role of the presence
of the human papillomavirus and the impact of targeted
therapies in this ﬁeld.
In rectal cancer the ROG investigated the possibility of
combining 5FU–Leucovorin (5FU−LV) with pre-operative
RT (pre-op RT). Through three consecutive phase II
studies the chemotherapy doses and schemes of 5FU−LV
to be used in a future phase III trial have been deﬁned. 34
Then the ROG started a large 4-arm phase III trial (EORTC
trial 22921) that evaluated the effect of adding 5FU−LV
pre-operatively, post-operatively or both in patients
receiving a long course of pre-op RT. The addition of
CT conferred a signiﬁcant beneﬁt on tumor sterilization
rate (5.3% with pre-op RT compared to 13.7% with
pre-op CRT), and on local control (5-year local recurrence
of 17.1% with RT compared to 8.7% with CRT). 35,36
Post-op CT appeared to increase survival in patients
who had a tumor response after the pre-operative
treatment. 37 This study was one of the three phase-III
trials that established pre-op CRT as a new paradigm
for the treatment of locally advanced resectable rectal
cancer.
Pooled analysis of data from the EORTC trial 22921 with
those of other European trials has further shown (1) that
abdomino-perineal excision was by itself associated
with an adverse outcome, (2) that diverting stomas
after pre-op CRT were associated with less symptomatic
anastomotic leakage, and (3) that anastomotic leakage
was associated with a signiﬁcant impaired outcome. 38
Another pooled analysis helped to construct nomograms
for predicting the outcome. 39
In the future, translational research (laboratory and
imaging) should be conducted to identify the patients
achieving a complete response after CRT not requiring
radical surgery and the patients with a high risk of
distant metastases amenable to new concepts such as
neoadjuvant chemotherapy.
3. Quality assurance in radiotherapy
During the 1980s, under the leadership of Emmanuel van
der Schueren, quality assurance (QA) in radiotherapy was
being developed and the ﬁrst publications of the group’s
ambitious projects appeared. 40−43 The crucial role of QA is
to guarantee the quality of radiotherapy data, namely in
terms of integrity, consistency, reliability and accuracy.
The work in this area has covered audits of ra-
diotherapy departments, dosimetry intercomparisons,
guidelines for writing radiotherapy protocols, design of
dummy run procedures (DR) and of individual case
reviews (ICR). Currently, with the installation of new
advanced equipment in many departments, updated
quality assurance measures are being applied and
centers are being credentialed for the use of new
treatment modalities within the framework of clinical
studies. Complex dosimetry checks and credentialing
of non-conventional radiotherapy techniques have thus
been added to the QA-armamentarium of the EORTC.
Complex dosimetry check can be performed either by
using a physical phantom, a benchmark case or a digital
phantom.The EORTC ROG, in close collaboration with the
Radiological Physics Center (RPC) in the United States of
America, has gained experience in performing Complex
dosimetry check using the former method. 44 Gradually,
the focus of QART has also been moving to the ﬁeld of
veriﬁcation of whether or not a participating institution
is able to deliver a radiation dose in full agreement
with its own treatment plan. These procedures have
becomemandatory since 2009 for any institution wishing
to use intensity-modulated radiotherapy (IMRT) before
site authorization. This constitutes a contemporary
QA benchmark to be implemented in future radiation
trials, using complex delivery techniques. It is axiomatic
to say that variations in compliance with protocol
treatment and/or suboptimal radiation delivery may
potentially lead to both loss of tumor local control and
increased radiation toxicity. 45
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Fig. 3 – EORTC modular integrated central review facility.
This work has continued with the constitution and
implementation of minimum requirements on stafﬁng
and infrastructure for centers entering patients in the
group’s clinical trials. The design and implementation
of a web-based Facility Questionnaire greatly facilitated
the submission and evaluation of data. The information
provided, which is to be regularly updated by all
group members, gives an insight into the structure and
stafﬁng of the participating departments, the available
equipment and local QA practices. 46
An EORTC Master Protocol for Phase III radiation
therapy studies was originally published in 1995 to
deﬁne, in a consistent sequence, the parameters which
must be addressed when designing a randomized trial
“from the rationale to the references”. 47 This was
originally implemented to assist study investigators
and writing committees and to increase homogeneity
of participation and data collection within the ROG
study protocols. However, radiotherapy preparation,
delivery, treatment veriﬁcation and QA have evolved
signiﬁcantly over the last 15 years, and clinical trial
protocols should therefore reﬂect these developments.
The Master Protocol was also instituted to help to
address disappointing QA in radiotherapy results of past
ROG studies which has since then been explained by
a number of factors including the misinterpretation of
protocol instructions. 48−51 The ROG protocol template
is currently under revision to address all known
potential areas of ambiguity in all steps of treatment
preparation, delivery and reporting of contemporary
advanced treatment techniques, such as IMRT.
The ROG has pioneered the implementation of elec-
tronic data transfer using a dedicated EORTC platform
for QA purposes. Currently, DR, ICR, complex dosime-
try check, and radiation techniques credentialing are
performed electronically, facilitating inter-institutional
digital exchange using DICOM-RT format datasets.
Figure 3 details the network architecture and the
streamlined process for electronic data transfer within
the central EORTC review facility. This QA platform
also integrates image data analysis software, ensuring
evaluation of target and non-target volumes for protocol-
compliance and more importantly to verify whether
volume delineation is appropriate, given the known
inter- and intra-variability of RT volume delineation by
physicians, potentially affecting patient’s outcome. 52
Following the example of biological translational
research performed after study closure, this QA elec-
tronic platform will allow us to perform analyses
of the inﬂuence of human factors and of technical
issues that may have a potential relevance in patients’
outcome, including tumor control probability, normal
tissue complication probability and quality of life. The
ability to store data centrally for future assessment will
strongly facilitate what is now a cumbersome process of
demanding RT data back from participating centers with
a possible loss of RT records/information.
After the death of Emmanuel van der Schueren
in 1998, a quality assurance fellowship program was
set up in his honor to support one-year fellowships
in radiotherapy QA at EORTC Headquarters with the
support of the Vlaamse Liga tegen Kanker. To date
eight fellows have taken up this position and the
ROG acknowledges their considerable contribution to RT
quality assurance in clinical trials.
4. Future challenges
During the past ten years the ROG has been one of
the most active EORTC groups, consistently accruing
between 600 and 1000 patients per year in group and
joint/intergroup studies. The future success of the group
will depend on its ability to embrace the new biological
targeted agents in combination with RT and to move
with the swiftly developing technology of treatment
delivery combined with its experience in QA of optimal
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radiation treatment for patients in clinical trials and
thereby ensuring valid study results.
One of the challenges faced by all groups conducting
clinical trials is the growing need to conduct intergroup
studies, because for some diseases international coop-
eration is required to achieve sufﬁcient patient accrual
in a timely manner. To promote global harmonization of
radiation oncology including quality assurance between
trial groups, the ROG was one of the founding
organizations of the Clinical Trials Radiotherapy QA
Harmonization Group. This group, in which major trial
groups from all over the world are represented, promotes
harmonization of radiation therapy including quality
assurance between trial groups, e.g. by providing a
platform for prospective discussions on new levels of QA
in radiotherapy, software tools, guidelines and policies of
trial groups. One of the ﬁrst tasks is the ongoing work of
a convention for naming the volume structures, organ at
risk (OAR) and Target Volumes used in clinical trials.
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